文献速递生殖医学

胚胎移植策略的成本效果:利用试管婴儿所生单胎和多胎的长期成本与结局构建决策分析模型

Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
PubMed 文献 · Hum Reprod · 2016-10-06

本研究用马尔可夫模型从社会视角比较选择性单胚胎移植(eSET)与双胚胎移植(DET)策略在1年、5年和18年时间跨度下的成本效果。短期(1年)eSET更具成本效果,但纳入中长期成本与结局后,在每获得1个质量调整生命年(QALY)支付2万欧元的阈值下DET成为最具成本效果的策略。

要点

  • 1年时间跨度下,3周期eSET最具成本效果,概率为99.9%。
  • 5年及18年时间跨度下,3周期DET最具成本效果,概率分别为77.3%和93.2%。
  • 18年时DETx3每对夫妇成本37871欧元,eSETx3为25563欧元。

核心结论

  • 短期(1年)视角下用单胚胎移植替代双胚胎移植具有成本效果,但纳入中期(5年)和长期(18年)成本与结局后,在每QALY支付2万欧元的阈值下DET成为最具成本效果的策略。

研究设计与样本

  • 马尔可夫模型,周期长度1年,时间跨度设为1年、5年和18年,比较最多3周期eSET、4周期eSET、5周期eSET、3周期标准治疗策略(STP,即<38岁且有优质胚胎者行eSET、其余行DET)和3周期DET五种策略。
  • 输入参数来自一项回顾性队列研究,收集了580对夫妇的医院资源数据,并发出父母问卷获得431份回复;进行了5000次迭代的概率敏感性分析。

主要发现

  • 18年时间跨度下,DETx3每对开始IVF的夫妇最有效(0.54次活产、10.2生命年、9.8 QALY)且费用最高(37871欧元)。
  • 3周期eSET最无效(0.43次活产、7.1生命年、6.8 QALY),费用为25563欧元。
  • 假设社会每QALY支付2万欧元,1年时间跨度下eSETx3最具成本效果的概率为99.9%。
  • 5年和18年时间跨度下DETx3最具成本效果,概率分别为77.3%和93.2%。

关键数值与推荐

  • 以每获得1个QALY支付2万欧元作为意愿支付阈值。
  • 1年时间跨度下eSETx3成为最具成本效果策略的概率为99.9%。
  • 5年时间跨度下DETx3成为最具成本效果策略的概率为77.3%。
  • 18年时间跨度下DETx3成为最具成本效果策略的概率为93.2%。

临床怎么用

  • 作者指出,当以儿童QALY作为结局指标时,长期看用单胚胎移植替代DET不具有成本效果。
  • 作者认为,为平衡考虑,家庭规划视角可能更可取,包括为希望再生育的夫妇增加治疗周期。
  • 作者建议分析应扩展至纳入家庭成员的QALY。

局限性

  • 这是首个在胚胎移植策略经济学评价中使用由儿童产生的QALY的研究。
  • 关于新生命产生的QALY是否应用于生育治疗经济学评价仍存在分歧。
  • 治疗在活产后即结束,且仅将儿童QALY作为效果指标。
  • 18年时间跨度的结果可能不够可靠,因8岁以后的数据基于外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the cost-effectiveness of elective single embryo transfer (eSET) versus double embryo transfer (DET) strategies from a societal perspective, when applying a time horizon of 1, 5 and 18 years? SUMMARY ANSWER: From a short-term perspective (1 year) it is cost-effective to replace DET with single embryo transfer; however when intermediate- (5 years) and long-term (18 years) costs and consequences are incorporated, DET becomes the most cost-effective strategy, given a ceiling ratio of €20 000 per quality-adjusted life years (QALY) gained. WHAT IS ALREADY KNOWN: According to previous cost-effectiveness research into embryo transfer strategies, DET is considered cost-effective if society is willing to pay around €20 000 for an extra live birth. However, interpretation of those studies is complicated, as those studies fail to incorporate long-term costs and outcomes and used live birth as a measure of effectiveness instead of QALYs. With this outcome, both multiple and singletons were valued as one live birth, whereas costs of all children of a multiple were incorporated. STUDY DESIGN, SIZE, DURATION: A Markov model (cycle length: 1 year; time horizon: 1, 5 and 18 years) was developed comparing a maximum of: (i) three cycles of eSET in all patients; (ii) four cycles of eSET in all patients; (iii) five cycles of eSET in all patients; (iv) three cycles of standard treatment policy (STP), i.e. eSET in women <38 years with a good quality embryo, and DET in all other women; and (v) three cycles of DET in all patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: Expected life years (LYs), child QALYs and costs were estimated for all comparators. Input parameters were derived from a retrospective cohort study, in which hospital resource data were collected (n=580) and a parental questionnaire was sent out (431 respondents). Probabilistic sensitivity analysis (5000 iterations) was performed. MAIN RESULTS AND THE ROLE OF CHANCE: With a time horizon of 18 years, DETx3 is most effective (0.54 live births, 10.2 LYs and 9.8 QALYs) and expensive (€37 871) per couple starting IVF. Three cycles of eSET are least effective (0.43 live births, 7.1 LYs and 6.8 QALYs) and expensive (€25 563). We assumed that society is willing to pay €20 000 per QALY gained. With a time horizon of 1 year, eSETx3 was the most cost-effective embryo transfer strategy with a probability of being cost-effective of 99.9%. With a time horizon of 5 or 18 years, DETx3 was most cost-effective, with probabilities of being cost-effective of 77.3 and 93.2%, respectively. LIMITATIONS, REASONS FOR CAUTION: This is the first study to use QALYs generated by the children in the economic evaluation of embryo transfer strategies. There remains some disagreement on whether QALYs generated by new life should be used in economic evaluations of fertility treatment. A further limitation is that treatment ends when it results in live birth and that only child QALYs were considered as measure of effectiveness. The results for the time horizon of 18 years might be less solid, as the data beyond the age of 8 years are based on extrapolation. WIDER IMPLICATIONS OF THE FINDINGS: The current Markov model indicates that when child QALYs are used as measure of outcome it is not cost-effective on the long term to replace DET with single embryo transfer strategies. However, for a balanced approach, a family-planning perspective would be preferable, including additional treatment cycles for couples who wish to have another child. Furthermore, the analysis should be extended to include QALYs of family members. STUDY FUNDING/COMPETING INTERESTS: This study was supported by a research grant (grant number 80-82310-98-09094) from the Netherlands Organization for Health Research and Development (ZonMw). There are no conflicts of interest in connection with this article. TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van Heesch MM, van Asselt AD, Evers JL, et al. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF. Hum Reprod. 2016. PMID: 27907897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。